Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity

  title={Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity},
  author={Tadashi Ishibashi and Tomoko Horisawa and Kumiko Tokuda and Takeo Ishiyama and Masaaki Ogasa and Rie Tagashira and Kenji Matsumoto and Hiroyuki Nishikawa and Y{\^o}ko Ueda and Satoko Toma and Hitomi Oki and Norihiko. Tanno and Ikutaro Saji and Akira Ito and Yukihiro Ohno and Mitsutaka Nakamura},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={171 - 181}
Lurasidone [(3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-ylmethyl]cyclohexylmethyl}hexahydro-4,7-methano-2H-isoindole-1,3-dione hydrochloride; SM-13496] is an azapirone derivative and a novel antipsychotic candidate. The objective of the current studies was to investigate the in vitro and in vivo pharmacological properties of lurasidone. Receptor binding affinities of lurasidone and several antipsychotic drugs were tested under comparable assay conditions using cloned… 

Figures and Tables from this paper

Binding of lurasidone, a novel antipsychotic, to rat 5-HT7 receptor: Analysis by [3H]SB-269970 autoradiography
The Role of 5-Hydroxytryptamine 7 Receptors in the Phencyclidine-Induced Novel Object Recognition Deficit in Rats
Results suggest 5-HT7 antagonism may contribute to the efficacy of some atypical APDs in the treatment of cognitive impairment in schizophrenia and may itself have some benefit in this regard.
Arene- and quinoline-sulfonamides as novel 5-HT7 receptor ligands.
Antidepressant-like activity and safety profile evaluation of 1H-imidazo[2,1-f]purine-2,4(3H,8H)-dione derivatives as 5-HT1A receptor partial agonists
It is demonstrated that AZ-853 and AZ-861, which structurally differ by one substituent and its placement in the phenyl ring, showed varied functional, pharmacological, and pharmacokinetic properties as well as side effect profiles.
Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist.
TPN672: A Novel Serotonin-Dopamine Activity Modulator for the Treatment of Schizophrenia
TPN672 displayed robust antipsychotic efficacy, significantly higher than aripiprazole in rodent models, and ameliorated negative symptoms and cognitive deficits in sociability test, dark avoidance response, Morris water maze test, and novel object recognition test.
5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux
The effects of lurasidone on the prefrontal cortex and hippocampus, DA efflux are dependent, at least partially, on its 5- HT1A agonist and 5-HT7 antagonist properties and may contribute to its efficacy to reverse the effects of subchronic phencyclidine treatment and improve schizophrenia.
The Novel Antipsychotic Drug Lurasidone Enhances N-Methyl-d-aspartate Receptor-Mediated Synaptic Responses
It is found that lurasidone, as well as the prototypical atypical APD clozapine, restored NMDAR-mediated synaptic responses to normal levels in the PCP model of schizophrenia, suggesting that NMD AR is the potential key molecular target of lurasidsone, possibility via antagonizing 5-HT7 receptors, which is consistent with evidence that 5- HT7 receptor antagonism contributes to cognitive enhancement by atypicals APDs in patients with schizophrenia.
Evaluation of dopamine D2/D3 and serotonin 5-HT2A receptor occupancy for a novel antipsychotic, lurasidone, in conscious common marmosets using small-animal positron emission tomography
Compared with olanzapine, lurasidone preferentially binds to D2/D3 receptors rather than 5-HT2A receptors in common marmosets, suggesting that the contribution of in vivo 5- HT2A receptor blocking activity to the pharmacological profile of lurasIDone might differ from olanZapine in terms of the low risk of extrapyramidal syndrome and efficacy against negative symptoms.


Pharmacological actions of SM-9018, a new neuroleptic drug with both potent 5-hydroxytryptamine2 and dopamine2 antagonistic actions.
The results suggest that SM-9018 is a new neuroleptic drug with both potent 5-HT2 and D2 antagonistic activities and with low cataleptogenic and central depressant activities.
The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent.
It is predicted that olanzapine will have an atypical profile and will be less likely to induce undesirable extrapyramidal symptoms than currently available drugs.
Effects of tandospirone, a novel anxiolytic agent, on human 5-HT 1A receptors expressed in Chinese hamster ovary cells (CHO cells)
Findings suggest that 5-HT 1A /CHO-No.5 cells retain 5- HT 1A receptor and Gi/o-protein coupling and that tandospirone acts as an agonist at human 5-ht 1A receptors.
Pharmacological properties of SM-3997: a new anxioselective anxiolytic candidate.
The results show that SM-3997 is a new anxioselective anxiolytic agent which is weaker than buspirone in the dopaminergic neuron system.
Serotonin receptors : their key role in drugs to treat schizophrenia
Binding profile of SM-9018, a novel antipsychotic candidate.
Results suggest that SM-9018 may be a novel antipsychotic agent with binding affinity for 5-HT2 and 5- HT1A receptors.
Lurasidone: a new drug in development for schizophrenia
Phase II efficacy data indicate that lurasidone doses from 40 to 120 mg/day are effective in the treatment of schizophrenia, with positive symptom reduction exceeding that for negative symptoms, as seen with other antipsychotics.
5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
The results confirm previous observations of the therapeutic efficacy of ritanserin on neuroleptic-induced parkinsonism, and support the hypothesis that serotonin influences extrapyramidal physiopathology.